EGFR-TKIs as first-line treatment have proved to significantly improve OS and DFS compared to chemotherapy in LA EGFR mutation-positive NSCLC [155,156,157,158,159], particularly in patients who are never-smokers, female, or present with adenocarcinoma histology with lepidic growth pattern [160,161,162]. The gene discussed is EGFR; the disease is adenocarcinoma.